Table 1.
Ceritinib treatment for ALK+ IMT
| Authors | Age (year) | Sex | ALK fusion | ALK inhibitor | Line | Response | PFS (months) | Other treatment |
|---|---|---|---|---|---|---|---|---|
| Trahair et al. [63] | 14.7 | M | RANBP2-ALK | Ceritinib | 2nd | CR | 42+ | Crizotinib (1st) |
| 9.1 | M | RNABP2-ALK | Ceritinib | 2nd | PR | 2 | Crizotinib (1st) | |
| Ono et al. [64] | 57 | M | RANBP2-ALK | Ceritinib | 2nd | PR | 11 | ASP3026 (1st) |
| Kyi et al. [65] | 58 | F | FN1-ALK | Ceritinib | 2nd | SD | 6 | Crizotinib (1st) |
| 68 | F | TNS1-ALK | Ceritinib | 3rd | PD | 2 | Crizotinib (1st), alectinib (2nd), lorlatinib (4th) | |
| 61 | F | LBH-ALK | Ceritinib | 2nd | SD | 6 | Crizotinib (1st), liposomal doxorubicin (3rd), lorlatinib (4th) | |
| 70 | F | IGFBP5 -ALK | Ceritinib | 1st | PR | 24+ | ||
| Tsakiri et al. [66] | 33 | M | TPM4-ALK | Ceritinib | 2nd | CR | 21+ | Crizotinib (1st) |
| Wang et al. [99] | 42 | F | PRRC2B-ALK | Ceritinib | 3rd | PR | 6 | Crizotinib (1st), alectinib (2nd), lorlatinib (4th) |
| Zhang et al. [100] | 22 | M | RRBP1-ALK | Ceritinib | 3rd | PR | 5+ | Crizotinib (1st), alectinib (2nd) |
| Yuan et al. [109] | 18 | F | NR | Ceritinib | 2nd | PR | 8 | Crizotinib (1st), alectinib (3rd), lorlatinib (4th) |
| Mittal et al. [120] | 11 months | F | NR | Ceritinib | 1st | CR | 6+ | |
| Brivio et al. [121] | 17 | M | NR | Ceritinib | 1st | CR | 26 | |
| NR | Ceritinib | 1st | CR | 36+ | ||||
| 14 | M | NR | Ceritinib | 1st | 70% reduction in size | 2 | ||
| Michels et al. [122] | 36 | F | DCTN1-ALK | Ceritinib | 2nd | Unconfirmed PR | 3.6 | Crizotinib (1st) |
| Mansfield et al. [123] | 32 | M | TPM3–ALK | Ceritinib | 2nd | Significant PR | 6+18 (post-surgery) | Crizotinib (1st) |
M male, F female, PD progressed disease, SD stable disease, PR partial response, CR complete response, NR not reported, ALK anaplastic lymphoma kinase, PRRC2B proline rich coiled-coil 2B, FN1 fibronectin 1, TNS1 tensin 1, LBH Limb Bud-Heart, IGFBP5 insulin like growth factor binding protein 5, RRBP1 ribosome-binding protein 1, RNABP2 RNA binding protein 2, TPM4 tropomyosin 4, DCTN1 dynactin subunit 1, TPM3 tropomyosin 3